Not yet recruitingN/A

Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)

NCT07585786 · LSD-RFPH · Northern Jiangsu People's Hospital

Closed to entry

Status

Not accepting participants

Not applicable

Phase

Target enrolment

—

Study sites

What it is testing

Summary

Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether LSD can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Serum creatinine (Scr) level
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24
Glomerular filtration rate (eGFR)
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24
BUN and UA level
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24
Urine albumin-to-creatinine ratio (UACR)
Measured over at preoperative baseline, postoperative month 1, month 3, month 6, month 12, month 18, month 24

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 80 Years

Ages

All

Sex

Not accepted

Healthy volunteers

Inclusion Criteria: 1. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging) 2. Splenomegaly and hypersplenism 3. History of portal hypertension bleeding (esophageal and gastric variceal bleeding ) 4. Age 18-80 years, male or female 5. Child-Pugh Class A or B liver function 6. No history of primary renal disease or acute kidney injury (AKI) 7. Signed written informed consent 8. Ability to complete 24-month follow-up Exclusion Criteria: 1. Child-Pugh Class C liver cirrhosis 2. Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.) 3. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection 4. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders 5. Hepatic encephalopathy or refractory ascites within 1 month before surgery 6. Pregnancy or lactation 7. Poor compliance, inability to complete follow-up

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07585786 on ClinicalTrials.gov →

Last updated in the registry 2026-05-18. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Indication

All 4 trials from Northern Jiangsu People's Hospital →